Inhibition of neovascularization by simultaneous inhibition of prostanoid ip and ep4 receptors
AssigneeAllergan, Inc.
InventorsJenny W. Wang, David F. Woodward
Life of this patent
Estimating the term…
Abstract
There are provided inter alia methods and compounds useful for decreasing neovascularization (e.g., choroidal neovascularization) in a subject in need thereof.
Claims15
A method for decreasing neovascularization in a subject in need thereof, comprising administering to said subject an effective amount of an IP receptor antagonist in combination with an effective amount of an EP4 receptor antagonist, thereby decreasing said neovascularization.
A pharmaceutical composition comprising an IP receptor antagonist, an EP4 receptor antagonist and a pharmaceutically acceptable excipient.
An ophthalmic pharmaceutical formulation comprising an ophthalmic pharmaceutical composition and an ophthalmic pharmaceutically acceptable excipient, said ophthalmic pharmaceutical composition comprising an IP receptor antagonist and an EP4 receptor antagonist.
Dependencies are inferred from the claim text.